Gradalis, a late-stage stage biotechnology company developing immunotherapies for multiple cancer indications, has named Steven Engle as Chief Executive Officer. Engle joins Gradalis with over two decades of executive leadership experience with public biotech companies developing breakthrough products in the metabolic, autoimmune, oncologic and infectious disease areas. He succeeds founder David Shanahan, who will continue as Gradalis’ Board Chair.